1. Home
  2. CRSP vs TRN Comparison

CRSP vs TRN Comparison

Compare CRSP & TRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • TRN
  • Stock Information
  • Founded
  • CRSP 2013
  • TRN 1933
  • Country
  • CRSP Switzerland
  • TRN United States
  • Employees
  • CRSP N/A
  • TRN N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • TRN Railroads
  • Sector
  • CRSP Health Care
  • TRN Industrials
  • Exchange
  • CRSP Nasdaq
  • TRN Nasdaq
  • Market Cap
  • CRSP 3.4B
  • TRN 3.1B
  • IPO Year
  • CRSP 2016
  • TRN N/A
  • Fundamental
  • Price
  • CRSP $40.53
  • TRN $38.21
  • Analyst Decision
  • CRSP Buy
  • TRN Buy
  • Analyst Count
  • CRSP 19
  • TRN 2
  • Target Price
  • CRSP $77.13
  • TRN $34.00
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • TRN 552.9K
  • Earning Date
  • CRSP 02-19-2025
  • TRN 02-20-2025
  • Dividend Yield
  • CRSP N/A
  • TRN 2.99%
  • EPS Growth
  • CRSP N/A
  • TRN 128.94
  • EPS
  • CRSP N/A
  • TRN 2.05
  • Revenue
  • CRSP $202,829,000.00
  • TRN $3,247,700,000.00
  • Revenue This Year
  • CRSP N/A
  • TRN $2.77
  • Revenue Next Year
  • CRSP $724.16
  • TRN N/A
  • P/E Ratio
  • CRSP N/A
  • TRN $16.97
  • Revenue Growth
  • CRSP 19.31
  • TRN 16.97
  • 52 Week Low
  • CRSP $36.52
  • TRN $23.64
  • 52 Week High
  • CRSP $91.10
  • TRN $39.00
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.09
  • TRN 62.98
  • Support Level
  • CRSP $36.52
  • TRN $37.24
  • Resistance Level
  • CRSP $40.99
  • TRN $38.12
  • Average True Range (ATR)
  • CRSP 1.78
  • TRN 0.95
  • MACD
  • CRSP 0.23
  • TRN 0.34
  • Stochastic Oscillator
  • CRSP 51.68
  • TRN 97.14

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About TRN Trinity Industries Inc.

Trinity Industries Inc. sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in three main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in the industries of agriculture, construction, consumer products, energy, and chemicals.

Share on Social Networks: